Bouissou François, Munzer Caroline, Decramer Stéphane, Roussel Bernard, Novo Robert, Morin Denis, Lavocat Marie Pierre, Guyot Claude, Taque Sophie, Fischbach Michel, Ouhayoun Eric, Loirat Chantal
Néphrologie Pédiatrique, Hôpital des Enfants, Université Paul Sabathier, Centre Hospitalier Universitaire Purpan, Toulouse, France.
Pediatrics. 2008 Mar;121(3):e553-60. doi: 10.1542/peds.2006-3632. Epub 2008 Feb 11.
We report a prospective, randomized, multicenter trial that compared the effect of 3 vs 8 days of intravenous ceftriaxone treatment on the incidence of renal scarring at 6 to 9 months of follow-up in 383 children with a first episode of acute pyelonephritis.
After initial treatment with intravenous netilmicin and ceftriaxone, patients were randomly assigned to either 5 days of oral antibiotics (short intravenous treatment) or 5 days of intravenous ceftriaxone (long intravenous treatment). Inclusion criteria were age 3 months to 16 years and first acute pyelonephritis episode, defined by fever of >38.5 degrees C, C-reactive protein level of >20 mg/L, and bacteriuria at >10(5)/mL. All patients underwent 99m technetium-dimercaptosuccinic acid scintigraphy 6 to 9 months after inclusion. A total of 548 children were included, 48 of whom were secondarily excluded and 117 of whom were lost to follow-up or had incomplete data; therefore, 383 children were eligible, 205 of them in the short intravenous treatment group and 178 in the long intravenous treatment group.
At inclusion, median age was 15 months, median duration of fever was 43 hours, and median C-reactive protein level was 122 mg/L. A total of 37% (143 of 383) of patients had a vesicoureteral reflux grades 1 to 3. Patient characteristics at inclusion were similar in both groups, except for a significantly higher proportion of girls in the short intravenous treatment group. The frequency of renal scars at scintigraphy was similar in both groups. Multivariate analysis demonstrated that renal scars were significantly associated with increased renal height at initial ultrasound and with the presence of grade 3 vesicoureteric reflux.
The incidence of renal scars was similar in patients who received 3 days compared 8 days of intravenous ceftriaxone. Increased renal height at initial ultrasound examination and grade 3 vesicoureteric reflux were significant risk factors for renal scars.
我们报告一项前瞻性、随机、多中心试验,该试验比较了3天与8天静脉注射头孢曲松治疗对383例首次发生急性肾盂肾炎的儿童在6至9个月随访时肾瘢痕形成发生率的影响。
在接受静脉注射奈替米星和头孢曲松初始治疗后,患者被随机分配接受5天口服抗生素治疗(短程静脉治疗)或5天静脉注射头孢曲松治疗(长程静脉治疗)。纳入标准为年龄3个月至16岁且首次发生急性肾盂肾炎,定义为体温>38.5℃、C反应蛋白水平>20mg/L以及细菌尿>10⁵/mL。所有患者在纳入后6至9个月接受锝-二巯基丁二酸闪烁扫描。共纳入548例儿童,其中48例被二次排除,117例失访或数据不完整;因此,383例儿童符合条件,其中205例在短程静脉治疗组,178例在长程静脉治疗组。
纳入时,中位年龄为15个月,中位发热持续时间为43小时,中位C反应蛋白水平为122mg/L。共有37%(383例中的143例)患者存在1至3级膀胱输尿管反流。纳入时两组患者的特征相似,但短程静脉治疗组女孩比例显著更高。闪烁扫描时肾瘢痕的发生率在两组中相似。多变量分析表明,肾瘢痕与初始超声检查时肾高度增加以及3级膀胱输尿管反流的存在显著相关。
接受3天与8天静脉注射头孢曲松治疗的患者肾瘢痕发生率相似。初始超声检查时肾高度增加和3级膀胱输尿管反流是肾瘢痕的重要危险因素。